Saturday, January 18, 2025
HomeTagsB Cell Medicines

B Cell Medicines

Be Bio Closes $92M Series C, Transitions to Clinical Stage

Be Biopharma, Inc, a leader in B Cell Medicines (BCMs), announced the closing of its $92M Series C financing. The round includes participation from...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics